97 filings
Page 2 of 5
8-K
jm831vdo5q a7
6 Nov 23
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
8:15am
8-K
1i9f3w52j44sqdkhxpp
18 Oct 23
Regulation FD Disclosure
11:31am
8-K
rc341bn dmd75pnz
26 Sep 23
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
8:30am
8-K
6ry5y x2cygp
10 Aug 23
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
8:15am
8-K
b2z0e9g3xtffd
29 Jun 23
Submission of Matters to a Vote of Security Holders
8:31am
8-K
i84zyliss2li6mp bttj
13 Jun 23
Based on forthcoming completion of patient enrollment and duration of follow-up in Cohort 2 from the phase 2 trial in late-stage NSCLC
8:31am
8-K
s1m6mg5heb
8 Jun 23
Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors
8:15am
ARS
qislhc3dmtctt4paqgz
23 May 23
Annual report to shareholders
8:01am
8-K
wrsu3 smf5u325
19 May 23
Regulation FD Disclosure
9:15am
8-K
vogptknu5ovtagd
11 May 23
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
8:31am
8-K
2en1oe1izm5c2xchu
9 May 23
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
5:02pm
8-K
dr68kk ev
17 Apr 23
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Non-Small Cell Lung Cancer
8:30am
S-8
9g86 dcoc
30 Mar 23
Registration of securities for employees
8:54am
8-K
dzetsj
30 Mar 23
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
8:30am
8-K
g655k3omkhe0csvm8
22 Feb 23
Regulation FD Disclosure
9:07am